Journal
of palliative medicine, Jul 2015, vol. 18, no. 7, p. 593-600
Bull, Janet,
Wellman, Charles V, Israel, Robert J, Barrett, Andrew C, Paterson, Craig,
Forbes, William P
The study objective was to assess safety and
efficacy of fixed-dose MNTX in two phase 4 trials. The authors report that fixed-dose
MNTX administered in the RCT and in a follow-up open label extension study demonstrated robust
efficacy and was well tolerated in treating OIC in patients with advanced
illness.